Click for best price
Aflibercept Biosimilars Market Size, Share 2022
Market Analysis and Insights: Global Aflibercept Biosimilars Market
The global Aflibercept Biosimilars market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Aflibercept Biosimilars market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Aflibercept Biosimilars market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Aflibercept Biosimilars market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Aflibercept Biosimilars market.
Global Aflibercept Biosimilars Scope and Market Size
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Segment by Application
- Wet Macular Degeneration
- Metastatic Colorectal Cancer
By Region
- North America
- United States
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
By Company
- Regeneron
- Sanofi
- Novartis
- Genentech
- Roche
- Pfizer
- Sartorius
- Eli Lilly
- Bayer
- Amgen
- PlantForm
- PharmaPraxis
- Samsung Bioepis
- Centus
- Cadila Pharmaceuticals
- Dr Reddy's
- Aurobindo Pharma
- Biocad
- MAbxience
- Hetero
- Biocon
- Kirin Biologics
- Mylan
- BeiGene
- Innovent
- Qilu Pharmaceutical
- Hengrui Pharmaceuticals
- Hisun Pharmaceutical
- TOT BIOPHARM
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Aflibercept Biosimilars product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Aflibercept Biosimilars, with price, sales, revenue, and global market share of Aflibercept Biosimilars from 2019 to 2022.
Chapter 3, the Aflibercept Biosimilars competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Aflibercept Biosimilars breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Aflibercept Biosimilars market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Aflibercept Biosimilars.
Chapter 13, 14, and 15, to describe Aflibercept Biosimilars sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Aflibercept Biosimilars Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global Aflibercept Biosimilars Market Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
121 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Aflibercept Biosimilars Market Overview
1.1 Product Overview and Scope of Aflibercept Biosimilars
1.2 Aflibercept Biosimilars Segment by Type
1.2.1 Global Aflibercept Biosimilars Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Intravitreal Injection
1.2.3 Intravenous Injection
1.3 Aflibercept Biosimilars Segment by Application
1.3.1 Global Aflibercept Biosimilars Sales Comparison by Application: (2022-2028)
1.3.2 Wet Macular Degeneration
1.3.3 Metastatic Colorectal Cancer
1.4 Global Aflibercept Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Aflibercept Biosimilars Revenue 2017-2028
1.4.2 Global Aflibercept Biosimilars Sales 2017-2028
1.4.3 Aflibercept Biosimilars Market Size by Region: 2017 Versus 2021 Versus 2028
2 Aflibercept Biosimilars Market Competition by Manufacturers
2.1 Global Aflibercept Biosimilars Sales Market Share by Manufacturers (2017-2022)
2.2 Global Aflibercept Biosimilars Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Aflibercept Biosimilars Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Aflibercept Biosimilars Manufacturing Sites, Area Served, Product Type
2.5 Aflibercept Biosimilars Market Competitive Situation and Trends
2.5.1 Aflibercept Biosimilars Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Aflibercept Biosimilars Players Market Share by Revenue
2.5.3 Global Aflibercept Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Aflibercept Biosimilars Retrospective Market Scenario by Region
3.1 Global Aflibercept Biosimilars Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Aflibercept Biosimilars Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Aflibercept Biosimilars Market Facts & Figures by Country
3.3.1 North America Aflibercept Biosimilars Sales by Country
3.3.2 North America Aflibercept Biosimilars Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Aflibercept Biosimilars Market Facts & Figures by Country
3.4.1 Europe Aflibercept Biosimilars Sales by Country
3.4.2 Europe Aflibercept Biosimilars Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Aflibercept Biosimilars Market Facts & Figures by Region
3.5.1 Asia Pacific Aflibercept Biosimilars Sales by Region
3.5.2 Asia Pacific Aflibercept Biosimilars Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Aflibercept Biosimilars Market Facts & Figures by Country
3.6.1 Latin America Aflibercept Biosimilars Sales by Country
3.6.2 Latin America Aflibercept Biosimilars Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Aflibercept Biosimilars Market Facts & Figures by Country
3.7.1 Middle East and Africa Aflibercept Biosimilars Sales by Country
3.7.2 Middle East and Africa Aflibercept Biosimilars Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Aflibercept Biosimilars Historic Market Analysis by Type
4.1 Global Aflibercept Biosimilars Sales Market Share by Type (2017-2022)
4.2 Global Aflibercept Biosimilars Revenue Market Share by Type (2017-2022)
4.3 Global Aflibercept Biosimilars Price by Type (2017-2022)
5 Global Aflibercept Biosimilars Historic Market Analysis by Application
5.1 Global Aflibercept Biosimilars Sales Market Share by Application (2017-2022)
5.2 Global Aflibercept Biosimilars Revenue Market Share by Application (2017-2022)
5.3 Global Aflibercept Biosimilars Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Regeneron
6.1.1 Regeneron Corporation Information
6.1.2 Regeneron Description and Business Overview
6.1.3 Regeneron Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Regeneron Aflibercept Biosimilars Product Portfolio
6.1.5 Regeneron Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Corporation Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Sanofi Aflibercept Biosimilars Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Corporation Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Novartis Aflibercept Biosimilars Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Genentech
6.4.1 Genentech Corporation Information
6.4.2 Genentech Description and Business Overview
6.4.3 Genentech Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Genentech Aflibercept Biosimilars Product Portfolio
6.4.5 Genentech Recent Developments/Updates
6.5 Roche
6.5.1 Roche Corporation Information
6.5.2 Roche Description and Business Overview
6.5.3 Roche Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Roche Aflibercept Biosimilars Product Portfolio
6.5.5 Roche Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Pfizer Aflibercept Biosimilars Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Sartorius
6.6.1 Sartorius Corporation Information
6.6.2 Sartorius Description and Business Overview
6.6.3 Sartorius Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Sartorius Aflibercept Biosimilars Product Portfolio
6.7.5 Sartorius Recent Developments/Updates
6.8 Eli Lilly
6.8.1 Eli Lilly Corporation Information
6.8.2 Eli Lilly Description and Business Overview
6.8.3 Eli Lilly Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Eli Lilly Aflibercept Biosimilars Product Portfolio
6.8.5 Eli Lilly Recent Developments/Updates
6.9 Bayer
6.9.1 Bayer Corporation Information
6.9.2 Bayer Description and Business Overview
6.9.3 Bayer Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Bayer Aflibercept Biosimilars Product Portfolio
6.9.5 Bayer Recent Developments/Updates
6.10 Amgen
6.10.1 Amgen Corporation Information
6.10.2 Amgen Description and Business Overview
6.10.3 Amgen Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Amgen Aflibercept Biosimilars Product Portfolio
6.10.5 Amgen Recent Developments/Updates
6.11 PlantForm
6.11.1 PlantForm Corporation Information
6.11.2 PlantForm Aflibercept Biosimilars Description and Business Overview
6.11.3 PlantForm Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.11.4 PlantForm Aflibercept Biosimilars Product Portfolio
6.11.5 PlantForm Recent Developments/Updates
6.12 PharmaPraxis
6.12.1 PharmaPraxis Corporation Information
6.12.2 PharmaPraxis Aflibercept Biosimilars Description and Business Overview
6.12.3 PharmaPraxis Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.12.4 PharmaPraxis Aflibercept Biosimilars Product Portfolio
6.12.5 PharmaPraxis Recent Developments/Updates
6.13 Samsung Bioepis
6.13.1 Samsung Bioepis Corporation Information
6.13.2 Samsung Bioepis Aflibercept Biosimilars Description and Business Overview
6.13.3 Samsung Bioepis Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Samsung Bioepis Aflibercept Biosimilars Product Portfolio
6.13.5 Samsung Bioepis Recent Developments/Updates
6.14 Centus
6.14.1 Centus Corporation Information
6.14.2 Centus Aflibercept Biosimilars Description and Business Overview
6.14.3 Centus Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Centus Aflibercept Biosimilars Product Portfolio
6.14.5 Centus Recent Developments/Updates
6.15 Cadila Pharmaceuticals
6.15.1 Cadila Pharmaceuticals Corporation Information
6.15.2 Cadila Pharmaceuticals Aflibercept Biosimilars Description and Business Overview
6.15.3 Cadila Pharmaceuticals Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Cadila Pharmaceuticals Aflibercept Biosimilars Product Portfolio
6.15.5 Cadila Pharmaceuticals Recent Developments/Updates
6.16 Dr Reddy's
6.16.1 Dr Reddy's Corporation Information
6.16.2 Dr Reddy's Aflibercept Biosimilars Description and Business Overview
6.16.3 Dr Reddy's Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Dr Reddy's Aflibercept Biosimilars Product Portfolio
6.16.5 Dr Reddy's Recent Developments/Updates
6.17 Aurobindo Pharma
6.17.1 Aurobindo Pharma Corporation Information
6.17.2 Aurobindo Pharma Aflibercept Biosimilars Description and Business Overview
6.17.3 Aurobindo Pharma Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.17.4 Aurobindo Pharma Aflibercept Biosimilars Product Portfolio
6.17.5 Aurobindo Pharma Recent Developments/Updates
6.18 Biocad
6.18.1 Biocad Corporation Information
6.18.2 Biocad Aflibercept Biosimilars Description and Business Overview
6.18.3 Biocad Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.18.4 Biocad Aflibercept Biosimilars Product Portfolio
6.18.5 Biocad Recent Developments/Updates
6.19 MAbxience
6.19.1 MAbxience Corporation Information
6.19.2 MAbxience Aflibercept Biosimilars Description and Business Overview
6.19.3 MAbxience Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.19.4 MAbxience Aflibercept Biosimilars Product Portfolio
6.19.5 MAbxience Recent Developments/Updates
6.20 Hetero
6.20.1 Hetero Corporation Information
6.20.2 Hetero Aflibercept Biosimilars Description and Business Overview
6.20.3 Hetero Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.20.4 Hetero Aflibercept Biosimilars Product Portfolio
6.20.5 Hetero Recent Developments/Updates
6.21 Biocon
6.21.1 Biocon Corporation Information
6.21.2 Biocon Aflibercept Biosimilars Description and Business Overview
6.21.3 Biocon Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.21.4 Biocon Aflibercept Biosimilars Product Portfolio
6.21.5 Biocon Recent Developments/Updates
6.22 Kirin Biologics
6.22.1 Kirin Biologics Corporation Information
6.22.2 Kirin Biologics Aflibercept Biosimilars Description and Business Overview
6.22.3 Kirin Biologics Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.22.4 Kirin Biologics Aflibercept Biosimilars Product Portfolio
6.22.5 Kirin Biologics Recent Developments/Updates
6.23 Mylan
6.23.1 Mylan Corporation Information
6.23.2 Mylan Aflibercept Biosimilars Description and Business Overview
6.23.3 Mylan Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.23.4 Mylan Aflibercept Biosimilars Product Portfolio
6.23.5 Mylan Recent Developments/Updates
6.24 BeiGene
6.24.1 BeiGene Corporation Information
6.24.2 BeiGene Aflibercept Biosimilars Description and Business Overview
6.24.3 BeiGene Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.24.4 BeiGene Aflibercept Biosimilars Product Portfolio
6.24.5 BeiGene Recent Developments/Updates
6.25 Innovent
6.25.1 Innovent Corporation Information
6.25.2 Innovent Aflibercept Biosimilars Description and Business Overview
6.25.3 Innovent Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.25.4 Innovent Aflibercept Biosimilars Product Portfolio
6.25.5 Innovent Recent Developments/Updates
6.26 Qilu Pharmaceutical
6.26.1 Qilu Pharmaceutical Corporation Information
6.26.2 Qilu Pharmaceutical Aflibercept Biosimilars Description and Business Overview
6.26.3 Qilu Pharmaceutical Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.26.4 Qilu Pharmaceutical Aflibercept Biosimilars Product Portfolio
6.26.5 Qilu Pharmaceutical Recent Developments/Updates
6.27 Hengrui Pharmaceuticals
6.27.1 Hengrui Pharmaceuticals Corporation Information
6.27.2 Hengrui Pharmaceuticals Aflibercept Biosimilars Description and Business Overview
6.27.3 Hengrui Pharmaceuticals Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.27.4 Hengrui Pharmaceuticals Aflibercept Biosimilars Product Portfolio
6.27.5 Hengrui Pharmaceuticals Recent Developments/Updates
6.28 Hisun Pharmaceutical
6.28.1 Hisun Pharmaceutical Corporation Information
6.28.2 Hisun Pharmaceutical Aflibercept Biosimilars Description and Business Overview
6.28.3 Hisun Pharmaceutical Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.28.4 Hisun Pharmaceutical Aflibercept Biosimilars Product Portfolio
6.28.5 Hisun Pharmaceutical Recent Developments/Updates
6.29 TOT BIOPHARM
6.29.1 TOT BIOPHARM Corporation Information
6.29.2 TOT BIOPHARM Aflibercept Biosimilars Description and Business Overview
6.29.3 TOT BIOPHARM Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.29.4 TOT BIOPHARM Aflibercept Biosimilars Product Portfolio
6.29.5 TOT BIOPHARM Recent Developments/Updates
7 Aflibercept Biosimilars Manufacturing Cost Analysis
7.1 Aflibercept Biosimilars Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Aflibercept Biosimilars
7.4 Aflibercept Biosimilars Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Aflibercept Biosimilars Distributors List
8.3 Aflibercept Biosimilars Customers
9 Aflibercept Biosimilars Market Dynamics
9.1 Aflibercept Biosimilars Industry Trends
9.2 Aflibercept Biosimilars Market Drivers
9.3 Aflibercept Biosimilars Market Challenges
9.4 Aflibercept Biosimilars Market Restraints
10 Global Market Forecast
10.1 Aflibercept Biosimilars Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Aflibercept Biosimilars by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Aflibercept Biosimilars by Type (2023-2028)
10.2 Aflibercept Biosimilars Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Aflibercept Biosimilars by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Aflibercept Biosimilars by Application (2023-2028)
10.3 Aflibercept Biosimilars Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Aflibercept Biosimilars by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Aflibercept Biosimilars by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Global Aflibercept Biosimilars Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Aflibercept Biosimilars Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Aflibercept Biosimilars Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Aflibercept Biosimilars Market Competitive Situation by Manufacturers in 2021
Table 5. Global Aflibercept Biosimilars Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Aflibercept Biosimilars Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Aflibercept Biosimilars Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Aflibercept Biosimilars Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Aflibercept Biosimilars Average Price (K USD/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Aflibercept Biosimilars Manufacturing Sites and Area Served
Table 11. Manufacturers Aflibercept Biosimilars Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Aflibercept Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Aflibercept Biosimilars as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Aflibercept Biosimilars Sales by Region (2017-2022) & (K Units)
Table 16. Global Aflibercept Biosimilars Sales Market Share by Region (2017-2022)
Table 17. Global Aflibercept Biosimilars Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Aflibercept Biosimilars Revenue Market Share by Region (2017-2022)
Table 19. North America Aflibercept Biosimilars Sales by Country (2017-2022) & (K Units)
Table 20. North America Aflibercept Biosimilars Sales Market Share by Country (2017-2022)
Table 21. North America Aflibercept Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Aflibercept Biosimilars Revenue Market Share by Country (2017-2022)
Table 23. Europe Aflibercept Biosimilars Sales by Country (2017-2022) & (K Units)
Table 24. Europe Aflibercept Biosimilars Sales Market Share by Country (2017-2022)
Table 25. Europe Aflibercept Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Aflibercept Biosimilars Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Aflibercept Biosimilars Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Aflibercept Biosimilars Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Aflibercept Biosimilars Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Aflibercept Biosimilars Revenue Market Share by Region (2017-2022)
Table 31. Latin America Aflibercept Biosimilars Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Aflibercept Biosimilars Sales Market Share by Country (2017-2022)
Table 33. Latin America Aflibercept Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Aflibercept Biosimilars Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Aflibercept Biosimilars Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Aflibercept Biosimilars Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Aflibercept Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Aflibercept Biosimilars Revenue Market Share by Country (2017-2022)
Table 39. Global Aflibercept Biosimilars Sales by Type (2017-2022) & (K Units)
Table 40. Global Aflibercept Biosimilars Sales Market Share by Type (2017-2022)
Table 41. Global Aflibercept Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Aflibercept Biosimilars Revenue Share by Type (2017-2022)
Table 43. Global Aflibercept Biosimilars Price by Type (2017-2022) & (K USD/Unit)
Table 44. Global Aflibercept Biosimilars Sales (K Units) by Application (2017-2022)
Table 45. Global Aflibercept Biosimilars Sales Market Share by Application (2017-2022)
Table 46. Global Aflibercept Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Aflibercept Biosimilars Revenue Share by Application (2017-2022)
Table 48. Global Aflibercept Biosimilars Price by Application (2017-2022) & (K USD/Unit)
Table 49. Regeneron Corporation Information
Table 50. Regeneron Description and Business Overview
Table 51. Regeneron Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 52. Regeneron Aflibercept Biosimilars Product
Table 53. Regeneron Recent Developments/Updates
Table 54. Sanofi Corporation Information
Table 55. Sanofi Description and Business Overview
Table 56. Sanofi Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 57. Sanofi Aflibercept Biosimilars Product
Table 58. Sanofi Recent Developments/Updates
Table 59. Novartis Corporation Information
Table 60. Novartis Description and Business Overview
Table 61. Novartis Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 62. Novartis Aflibercept Biosimilars Product
Table 63. Novartis Recent Developments/Updates
Table 64. Genentech Corporation Information
Table 65. Genentech Description and Business Overview
Table 66. Genentech Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 67. Genentech Aflibercept Biosimilars Product
Table 68. Genentech Recent Developments/Updates
Table 69. Roche Corporation Information
Table 70. Roche Description and Business Overview
Table 71. Roche Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 72. Roche Aflibercept Biosimilars Product
Table 73. Roche Recent Developments/Updates
Table 74. Pfizer Corporation Information
Table 75. Pfizer Description and Business Overview
Table 76. Pfizer Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 77. Pfizer Aflibercept Biosimilars Product
Table 78. Pfizer Recent Developments/Updates
Table 79. Sartorius Corporation Information
Table 80. Sartorius Description and Business Overview
Table 81. Sartorius Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 82. Sartorius Aflibercept Biosimilars Product
Table 83. Sartorius Recent Developments/Updates
Table 84. Eli Lilly Corporation Information
Table 85. Eli Lilly Description and Business Overview
Table 86. Eli Lilly Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 87. Eli Lilly Aflibercept Biosimilars Product
Table 88. Eli Lilly Recent Developments/Updates
Table 89. Bayer Corporation Information
Table 90. Bayer Description and Business Overview
Table 91. Bayer Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 92. Bayer Aflibercept Biosimilars Product
Table 93. Bayer Recent Developments/Updates
Table 94. Amgen Corporation Information
Table 95. Amgen Description and Business Overview
Table 96. Amgen Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 97. Amgen Aflibercept Biosimilars Product
Table 98. Amgen Recent Developments/Updates
Table 99. PlantForm Corporation Information
Table 100. PlantForm Description and Business Overview
Table 101. PlantForm Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 102. PlantForm Aflibercept Biosimilars Product
Table 103. PlantForm Recent Developments/Updates
Table 104. PharmaPraxis Corporation Information
Table 105. PharmaPraxis Description and Business Overview
Table 106. PharmaPraxis Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 107. PharmaPraxis Aflibercept Biosimilars Product
Table 108. PharmaPraxis Recent Developments/Updates
Table 109. Samsung Bioepis Corporation Information
Table 110. Samsung Bioepis Description and Business Overview
Table 111. Samsung Bioepis Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 112. Samsung Bioepis Aflibercept Biosimilars Product
Table 113. Samsung Bioepis Recent Developments/Updates
Table 114. Centus Corporation Information
Table 115. Centus Description and Business Overview
Table 116. Centus Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 117. Centus Aflibercept Biosimilars Product
Table 118. Centus Recent Developments/Updates
Table 119. Cadila Pharmaceuticals Corporation Information
Table 120. Cadila Pharmaceuticals Description and Business Overview
Table 121. Cadila Pharmaceuticals Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 122. Cadila Pharmaceuticals Aflibercept Biosimilars Product
Table 123. Cadila Pharmaceuticals Recent Developments/Updates
Table 124. Dr Reddy's Corporation Information
Table 125. Dr Reddy's Description and Business Overview
Table 126. Dr Reddy's Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 127. Dr Reddy's Aflibercept Biosimilars Product
Table 128. Dr Reddy's Recent Developments/Updates
Table 129. Aurobindo Pharma Corporation Information
Table 130. Aurobindo Pharma Description and Business Overview
Table 131. Aurobindo Pharma Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 132. Aurobindo Pharma Aflibercept Biosimilars Product
Table 133. Aurobindo Pharma Recent Developments/Updates
Table 134. Biocad Corporation Information
Table 135. Biocad Description and Business Overview
Table 136. Biocad Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 137. Biocad Aflibercept Biosimilars Product
Table 138. Biocad Recent Developments/Updates
Table 139. MAbxience Corporation Information
Table 140. MAbxience Description and Business Overview
Table 141. MAbxience Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 142. MAbxience Aflibercept Biosimilars Product
Table 143. MAbxience Recent Developments/Updates
Table 144. Hetero Corporation Information
Table 145. Hetero Description and Business Overview
Table 146. Hetero Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 147. Hetero Aflibercept Biosimilars Product
Table 148. Hetero Recent Developments/Updates
Table 149. Biocon Corporation Information
Table 150. Biocon Description and Business Overview
Table 151. Biocon Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 152. Biocon Aflibercept Biosimilars Product
Table 153. Biocon Recent Developments/Updates
Table 154. Kirin Biologics Corporation Information
Table 155. Kirin Biologics Description and Business Overview
Table 156. Kirin Biologics Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 157. Kirin Biologics Aflibercept Biosimilars Product
Table 158. Kirin Biologics Recent Developments/Updates
Table 159. Mylan Corporation Information
Table 160. Mylan Description and Business Overview
Table 161. Mylan Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 162. Mylan Aflibercept Biosimilars Product
Table 163. Mylan Recent Developments/Updates
Table 164. BeiGene Corporation Information
Table 165. BeiGene Description and Business Overview
Table 166. BeiGene Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 167. BeiGene Aflibercept Biosimilars Product
Table 168. BeiGene Recent Developments/Updates
Table 169. Innovent Corporation Information
Table 170. Innovent Description and Business Overview
Table 171. Innovent Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 172. Innovent Aflibercept Biosimilars Product
Table 173. Innovent Recent Developments/Updates
Table 174. Qilu Pharmaceutical Corporation Information
Table 175. Qilu Pharmaceutical Description and Business Overview
Table 176. Qilu Pharmaceutical Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 177. Qilu Pharmaceutical Aflibercept Biosimilars Product
Table 178. Qilu Pharmaceutical Recent Developments/Updates
Table 179. Hengrui Pharmaceuticals Corporation Information
Table 180. Hengrui Pharmaceuticals Description and Business Overview
Table 181. Hengrui Pharmaceuticals Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 182. Hengrui Pharmaceuticals Aflibercept Biosimilars Product
Table 183. Hengrui Pharmaceuticals Recent Developments/Updates
Table 184. Hisun Pharmaceutical Corporation Information
Table 185. Hisun Pharmaceutical Description and Business Overview
Table 186. Hisun Pharmaceutical Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 187. Hisun Pharmaceutical Aflibercept Biosimilars Product
Table 188. Hisun Pharmaceutical Recent Developments/Updates
Table 189. TOT BIOPHARM Corporation Information
Table 190. TOT BIOPHARM Description and Business Overview
Table 191. TOT BIOPHARM Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 192. TOT BIOPHARM Aflibercept Biosimilars Product
Table 193. TOT BIOPHARM Recent Developments/Updates
Table 194. Production Base and Market Concentration Rate of Raw Material
Table 195. Key Suppliers of Raw Materials
Table 196. Aflibercept Biosimilars Distributors List
Table 197. Aflibercept Biosimilars Customers List
Table 198. Aflibercept Biosimilars Market Trends
Table 199. Aflibercept Biosimilars Market Drivers
Table 200. Aflibercept Biosimilars Market Challenges
Table 201. Aflibercept Biosimilars Market Restraints
Table 202. Global Aflibercept Biosimilars Sales Forecast by Type (2023-2028) & (K Units)
Table 203. Global Aflibercept Biosimilars Sales Market Share Forecast by Type (2023-2028)
Table 204. Global Aflibercept Biosimilars Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 205. Global Aflibercept Biosimilars Revenue Market Share Forecast by Type (2023-2028)
Table 206. Global Aflibercept Biosimilars Sales Forecast by Application (2023-2028) & (K Units)
Table 207. Global Aflibercept Biosimilars Sales Market Share Forecast by Application (2023-2028)
Table 208. Global Aflibercept Biosimilars Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 209. Global Aflibercept Biosimilars Revenue Market Share Forecast by Application (2023-2028)
Table 210. Global Aflibercept Biosimilars Sales Forecast by Region (2023-2028) & (K Units)
Table 211. Global Aflibercept Biosimilars Sales Market Share Forecast by Region (2023-2028)
Table 212. Global Aflibercept Biosimilars Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 213. Global Aflibercept Biosimilars Revenue Market Share Forecast by Region (2023-2028)
Table 214. Research Programs/Design for This Report
Table 215. Key Data Information from Secondary Sources
Table 216. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Aflibercept Biosimilars
Figure 2. Global Aflibercept Biosimilars Market Share by Type in 2021 & 2028
Figure 3. Intravitreal Injection Product Picture
Figure 4. Intravenous Injection Product Picture
Figure 5. Global Aflibercept Biosimilars Market Share by Application in 2021 & 2028
Figure 6. Wet Macular Degeneration
Figure 7. Metastatic Colorectal Cancer
Figure 8. Global Aflibercept Biosimilars Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 9. Global Aflibercept Biosimilars Market Size (2017-2028) & (US$ Million)
Figure 10. Global Aflibercept Biosimilars Sales (2017-2028) & (K Units)
Figure 11. Aflibercept Biosimilars Sales Share by Manufacturers in 2021
Figure 12. Global Aflibercept Biosimilars Revenue Share by Manufacturers in 2021
Figure 13. The Global 5 and 10 Largest Aflibercept Biosimilars Players: Market Share by Revenue in 2021
Figure 14. Aflibercept Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 15. Global Aflibercept Biosimilars Sales Market Share by Region (2017-2022)
Figure 16. Global Aflibercept Biosimilars Sales Market Share by Region in 2021
Figure 17. Global Aflibercept Biosimilars Revenue Market Share by Region (2017-2022)
Figure 18. Global Aflibercept Biosimilars Revenue Market Share by Region in 2021
Figure 19. United States Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 20. Canada Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 21. Germany Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. France Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. U.K. Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. Italy Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Russia Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. China Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Japan Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. South Korea Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. India Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Australia Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. China Taiwan Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Indonesia Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Thailand Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Malaysia Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Mexico Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Brazil Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Argentina Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Turkey Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Saudi Arabia Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. UAE Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Sales Market Share of Aflibercept Biosimilars by Type (2017-2022)
Figure 42. Manufacturing Cost Structure of Aflibercept Biosimilars
Figure 43. Manufacturing Process Analysis of Aflibercept Biosimilars
Figure 44. Aflibercept Biosimilars Industrial Chain Analysis
Figure 45. Channels of Distribution
Figure 46. Distributors Profiles
Figure 47. Bottom-up and Top-down Approaches for This Report
Figure 48. Data Triangulation
Figure 49. Key Executives Interviewed
